115 results
Page 4 of 6
6-K
EX-99.1
mrwzw9nf
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.2
2bp kx297
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
o2vtmh5yf 40
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm
6-K
EX-99.1
zjmmhus8cizh0icm28
15 Apr 21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study
7:30am
6-K
EX-99.1
bx82vwi77 n57uoqkx8
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
424B5
38ojt5308a72zmq37
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
74kmosgs6j1u7
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
vl1mkg
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
uo5tqc9ishog5c
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.1
em33gx ep91h0
5 Jan 21
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
7:30am
6-K
EX-99.2
w01vahqtcj4
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.3
oeqfin 8iqrsv9
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
67h8a
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.2
m51hgcjown5o swu
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.3
q47rcu
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
vu2 itmlfc4
30 Jul 20
Current report (foreign)
7:36am
424B5
n77gh8wz263pbfi
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
o25oyyvfxpo8
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.2
8ph6e9zdq21s2
21 May 20
Current report (foreign)
8:09am